Literature DB >> 27699752

[RIT1: a novel gene associated with Noonan syndrome].

I Arroyo-Carrera1,2, M Solo de Zaldivar-Tristancho1, R Martin-Fernandez1, M Vera-Torres1, J F Gonzalez de Buitrago-Amigo1, J Botet-Rodriguez3.   

Abstract

INTRODUCTION: Noonan syndrome is the most frequent of the congenital group of malformation syndromes caused by germline mutations that encode components of the RAS/MAPK pathway, termed RASopathies, one of the most frequent congenital genetic disorders in the clinical practice. Recently RIT1 mutations have been reported in patients with Noonan syndrome. CASE REPORT: A 7 years-old girl with a clinical diagnosis of Noonan syndrome, and with a hypertrophic cardiomyopathy included in her clinical manifestations, where a de novo heterozygous, probably pathogenic, novel mutation in RIT1, c.295T>C (p.Phe99Leu), has been identified.
CONCLUSIONS: RIT1 shares homology with other RAS proteins and the expression of mutant alleles demonstrates a gain-of-function effect supporting a causative role in Noonan syndrome pathogenesis. Data suggest that the frequency of RIT1 mutations can be estimated as 3-5% in Noonan syndrome patients. These cases compared with Noonan patients harboring mutations in other genes are characterized by high frequency of prenatal abnormalities and hypertrophic cardiomyopathy, and lower frequencies of short stature and pectus abnormalities. We emphasize the importance of the novel identified genes in order to be included in the diagnostic panels.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27699752

Source DB:  PubMed          Journal:  Rev Neurol        ISSN: 0210-0010            Impact factor:   0.870


  2 in total

1.  Small GTPase RIT1 in Mouse Retina; Cellular and Functional Analysis.

Authors:  Sajad Mir; Douglas A Andres
Journal:  Curr Eye Res       Date:  2018-06-25       Impact factor: 2.424

2.  The molecular functions of RIT1 and its contribution to human disease.

Authors:  Richard Van; Antonio Cuevas-Navarro; Pau Castel; Frank McCormick
Journal:  Biochem J       Date:  2020-08-14       Impact factor: 3.857

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.